France's Sartorius Stedim Biotech 9-month revenue up 6.5%

Overview

• France bioprocessing technology firm's 9-month revenue rose 6.5% in constant currencies

• Adjusted EBITDA for 9 months increased 4.8% yr/yr

• Company confirmed and refined full-year 2026 guidance

Outlook

• Company continues to expect 2026 sales revenue growth of 6-10% in constant currencies

• Company expects 2026 underlying EBITDA margin to be slightly above 31%

• Company now expects 2026 capital expenditure to sales revenue ratio of about 13%

Result Drivers

• RECURRING CONSUMABLES - Co said recurring business with consumables remained the main driver of revenue growth

• EQUIPMENT SALES - Growth in bioprocess equipment contributed to higher sales, according to the company

• VOLUME AND SCALE - Positive volume effects and economies of scale offset product mix effects, supporting profitability

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Sartorius Stedim Biotech SA is €242.50, about 12.6% above its October 21 closing price of €215.40

Reuters Recommended Reads

• Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

• Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

• Oct 21 - Medpace Q3 revenue rises 8.5%, slightly beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)